Unique ID issued by UMIN | UMIN000006393 |
---|---|
Receipt number | R000007568 |
Scientific Title | Cross-sectional study of second-line therapy administration after platinum-based chemotherapy for patients with advanced NSCLC. |
Date of disclosure of the study information | 2011/09/22 |
Last modified on | 2020/08/19 13:55:24 |
Cross-sectional study of second-line therapy administration after
platinum-based chemotherapy for patients with advanced NSCLC.
Second-line chemotherapy administration for patients with advanced NSCLC, who completed platinum-based "Hyojun" (standard) doublet, In the follow-up period, and at recurrence.(SAPPHIRE)
Cross-sectional study of second-line therapy administration after
platinum-based chemotherapy for patients with advanced NSCLC.
Second-line chemotherapy administration for patients with advanced NSCLC, who completed platinum-based "Hyojun" (standard) doublet, In the follow-up period, and at recurrence.(SAPPHIRE)
Japan |
Advanced lung cancer
Pneumology | Hematology and clinical oncology | Chest surgery |
Malignancy
NO
To investigate the proportion of the second-line therapy administration after platinum-based chemotherapy for patients with advanced NSCLC, and explore the reasons and the background factors of the patients who could not take the second-line therapy. We also discuss the strategy for the follow-up of patients after the first-line chemotherapy (maintenance chemotherapy, periodical follow-up without continuing chemotherapy), by comparing the background factors at the beginning of the first and second line chemotherapy.
Others
horyuu
Exploratory
Pragmatic
Not applicable
Proportion of the patients administered the second-line chemotherapy
1)Proportion of the patients who had PD for first-line chemotherapy
2)Proportion of the patients who were administered second-line chemotherapy
3)Proportion of the patients who were administered third-line chemotherapy after the second-line chemotherapy
4)Proportion of the patients who were administered second-line chemotherapy after having PD for first-line chemotherapy.
5)Proportion of the patients who were administered second-line chemotherapy after taking maintenance chemotherapy.
Observational
Not applicable |
Not applicable |
Male and Female
1)Patients who were diagnosed as advanced or recurrent NSCLC before this study.
2)Consecutive patients in each institution who had started first-line platinum chemotherapy in combination with third generation agent after April 1, 2010.
1)Recurrent NSCLC patients who had undergone adjuvant platinum based chemotherapy.
2)Active double cancer.
750
1st name | Hideo |
Middle name | |
Last name | Kunitoh |
Mitsui Memorial Hospital
Department of Respiratory Medicine
101-8643
1,Kanndaizumi-chou, Chiyoda-ku, Tokyo, 101-8643, Japan
03-3862-9111
no@mail
1st name | Akira |
Middle name | |
Last name | Yamao |
Public Health Research Foundation
Comprehensive Support Project for Clinical Research
169-0051
1-1-7, Nishiwaseda, Shinjuku-ku, Tokyo, 169-0051, Japan
03-5287-2633
http://www.csp.or.jp/
info@csp.or.jp
SAPPHIRE Executive committee
Public Health Research Foundation
Other
no
no
no
nomail
NO
2011 | Year | 09 | Month | 22 | Day |
Unpublished
No longer recruiting
2010 | Year | 09 | Month | 03 | Day |
2010 | Year | 10 | Month | 01 | Day |
2013 | Year | 03 | Month | 01 | Day |
horyuu
2011 | Year | 09 | Month | 22 | Day |
2020 | Year | 08 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007568
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |